Category: Alkido Pharma

NEW YORK, Aug. 14, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 11:20 a.m. ET.  Anthony Hayes, CEO of AIkido Pharma Inc. will be presenting to a live audience.

Register here: https://ld-micro-conference.events.issuerdirect.com/

“We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space,” stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View AIkido Pharma’s profile here: http://www.ldmicro.com/profile/AIKI

Profiles powered by LD Micro — News Compliments of Accesswire

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming “500” in September is the Company’s most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-to-present-at-the-ld-500-virtual-conference-301112317.html

SOURCE AIkido Pharma Inc.

NEW YORK, Aug. 11, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) today announced it has extended its previously disclosed exclusive option agreement (“Option”) with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 “Methods of Treating Coronavirus Infection.” The present invention provides methods for treating a coronavirus infection.  The initial Option for Treatment of Coronavirus was previously disclosed on March 6, 2020.  The Option has been extended until December 2, 2020.  All other terms and conditions of the original Option agreement remain in full force and effect.

This invention was made with government support under Grant Number AI095569 awarded by the National Institutes of Health. As result, the NIH has certain rights in the invention.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/option-for-treatment-for-coronavirus-extended-301109887.html

SOURCE AIkido Pharma Inc.

NEW YORK, Aug. 3, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on July 31, 2020, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ’s requirements when the closing bid price for the Company’s common stock was at or above $1.00 for ten consecutive business days.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-301104540.html

SOURCE AIkido Pharma Inc.

NEW YORK, July 9, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. As previously announced, on April 13, 2020, AIkido executed a Master License Agreement with the University of Maryland, Baltimore (“UMB”), covering certain antiviral compounds discovered by UMB.

Recently, the researchers at UMB, including Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine (UMSOM),  Alexander MacKerell, PhD, Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, and Stuart Weston, PhD, Postdoctoral Fellow at UMSOM, have identified a human protein complex (called the SKI complex) that is important for replication of several viruses including Influenza, COVID-19, SARS1, MERS, SARS2, Ebola and Marburg.  Using a computer modeling approach called SILCS from SilcsBio LLC, chemical compounds were identified that are predicted to bind to a pocket on a human protein in this complex. These compounds were tested for their ability to block replication of the Influenza virus in human cells, from which several active compounds were found. These compounds were then tested against the other viruses and found to block replication of these as well. Utilizing the information gleaned from this initial research and the power of the SILCS technology combined with machine learning tools, the researchers are currently identifying compounds with chemical structures similar to the active compounds and testing them to find ones that work better at blocking virus replication.

“This is encouraging progress, demonstrating the importance of machine learning to accelerate pharmaceutical research,” commented Anthony Hayes, CEO of AIkido. “Legacy processes, involving manually testing potentially thousands of compounds, are slower and potentially more expensive. Utilizing a combination of a physics-based approach and machine learning, our partners are able to significantly narrow the range of potential compounds to test, accelerating efforts and significantly reducing costs. The ultimate goal is to create a new compound that blocks replication of a wide variety of viruses in humans that will be an effective drug for the treatment of known viral infections as well as those that may arise in the future.”

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

 

View original content:http://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-key-progress-in-computational-approaches-to-identify-virus-treatments-including-coronavirus-301091089.html

SOURCE AIkido Pharma Inc.

NEW YORK, June 26, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced an update to its machine learning driven pancreatic cancer research.

As previously reported, the Company executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center and Cogia BioTech to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. This work has recently identified 100 candidate markers of early and late stage pancreatic cancer, in human and preclinical models.  Moving forward, the work will stage diagnostic markers, test prognostic indicators, and help identify drugs best suited for individual patient treatment.

Anthony Hayes, CEO of AIkido stated, “Machine learning is an important contributor to this work and to the future of oncology drug development and treatment, and the research to date is encouraging. We hope this effort will help extend life for pancreatic cancer patients.”

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-provides-update-to-machine-learning-pancreatic-cancer-research-301084406.html

SOURCE AIkido Pharma Inc.

NEW YORK, May 28, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) today announced publication of a paper: The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C by Peter M. Alexander, Gregory L. Kucera, Kristin M. Pladna and Timothy S. Pardee in the July 2020 issue of Translational Oncology. The paper documents the results from the company’s sponsored research at Wake Forest University.

The article reviews the approach to treating Acute Myeloid Leukemia (AML), an aggressive malignancy with poor outcomes. Nucleoside analogs are subject to resistance mechanisms including downregulation of equilibrative nucleoside transporter (ENT1) and deoxycytidine kinase (dCK). KPC34 is a novel phospholipid mimetic that when cleaved by phospholipase C (PLC) liberates gemcitabine monophosphate and a diacylglycerol mimetic that inhibits the classical isoforms of protein kinase C (PKC). KPC34 acts independently of ENT1 and dCK. KPC34 was active against all AML cell lines tested with IC50s in the nanomolar range. Enforced expression of PLC increased response to KPC34 in vivo. In an orthotopic, xenograft model, KPC34 treatment resulted in a significant increase in survival compared to control animals and those treated with high-dose cytarabine. In a PDX model with activated PKC, there was a significant survival benefit with KPC34, and at progression, there was attenuation of PKC activation in the resistant cells. In contrast, KPC34 was ineffective against a syngeneic, orthotopic AML model without activated PKC. However, when cells from that model were forced to express PKC, there were significantly increased sensitivity in vitro and survival benefit in vivo. These data suggest that KPC34 is active against AML and that the presence of activated PKC can be a predictive biomarker.

Anthony Hayes, CEO of AIkido stated, “Wake Forest University is a world-class research facility and an outstanding partner for AIkido. This detailed research report helps to quantify the expected benefits of our novel approach to this aggressive disease with what we hope will be a transformative solution.”

The published paper is available at https://www.sciencedirect.com/science/article/pii/S1936523320300279

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-publication-of-results-from-sponsored-research-at-wake-forest-university-301067037.html

SOURCE AIkido Pharma Inc.

NEW YORK, May 19, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the distribution of the previously announced Hoth Therapeutics, Inc. (“Hoth”) stock dividend, has commenced and stockholders will receive their dividend in the next few days by mail or electronic deposit.

Each stockholder of the Company, as of 5:00 p.m. Eastern Time on April 30, 2020, will be receiving one (1) share of Hoth common stock for every five hundred (500) shares of AIkido common stock held.  No further action by stockholders is necessary to receive the distribution.

The Company would like to thank all the parties that assisted with this dividend, including DTCC and Morgan Stanley.  We also thank your shareholders for their patience.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-distribution-of-hoth-dividend-301061765.html

SOURCE AIkido Pharma Inc.

NEW YORK, May 8, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Hoth Therapeutics Inc. registered the stock to be distributed on April 3 2020.(https://www.sec.gov/Archives/edgar/data/1711786/000121390020008546/ea120229-s1_hoththerape.htm). The registration was declared effective and the Prospectus was filed on May 7, 2020.(https://www.sec.gov/Archives/edgar/data/1711786/000121390020011222/ea121442-424b3_hoththerap.htm). We thank Hoth for their assistance.

In order to effectuate the distribution, the physical stock certificate underlying the shares of Hoth common stock held by AIkido must be physically delivered to Hoth’s transfer agent. That physical stock certificate is currently being held in a vault at The Depository Trust Company (“DTC”) (https://www.dtcc.com). The Company has been advised by DTC that unfortunately, due to ongoing concerns related to the current global COVID-19 pandemic, DTC has issued an alert (https://www.dtcc.com/-/media/Files/pdf/2020/4/30/13352-20.pdf) notifying companies that all “Physical Securities Processing” services are currently suspended and DTC will reassess the current circumstances and provide an update on Friday, May 15, 2020. Until DTC resumes “Physical Securities Processing”, DTC is unable to deliver the physical stock certificate underlying the shares of Hoth common stock to Hoth’s transfer agent, resulting in a delay of the actual distribution.

The Company will update stockholders on the date of distribution as soon as possible. Stockholders should note that the record date for the distribution has not changed and individuals who were stockholders at 5:00 p.m. on April 30, 2020 will still be receiving the distribution. No further action by shareholders is necessary to receive the distribution. We regret the delay and frustration this may cause the Company’s stockholders.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-provides-update-on-distribution-date-for-hoth-dividend-distribution-301056001.html

SOURCE AIkido Pharma Inc.

NEW YORK, May 6, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD (“Cogia”) (www.cogia.de) to accelerate the Company’s pancreatic cancer genetic marker research.  Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development.  Cogia provides state-of-the-art digital information and discovery tools to subject-matter experts and scientists working in genetics and cancer research, to advance drug development.  Cogia’s existing clients include many international companies, including international pharmaceutical companies.

Cogia will augment the Company’s efforts of using machine learning to find genetic markers that could lead to pancreatic cancer. As with many cancers, early detection is vital, but in pancreatic cancer, surgical intervention is currently the only effective treatment for the extension of life. Pancreatic cancer is relatively rare; however, it is the third leading cause of cancer deaths in the United States.  The disease is often asymptomatic, making early detection and treatment difficult or even impossible. Only 20% of individuals are diagnosed with pancreatic cancer early enough to be surgical candidates. Reliable markers for early detection will expand the number of patients who are eligible for life-extending surgery.

Andreas Typaldos, Executive Chairman of Cogia Biotech, expressed his excitement about the research agreement with AIkido. “Even during the preparatory work leading up to this strategic agreement with AIkido, one could see the promise of compelling outcomes in early and better detection of pancreatic cancer and possibility for novel and more effective therapeutics using state-of-the-art technologies like AI and ML. The very earliest project-design work sessions between Cogia Biotech AI/ML data scientists, bio-informatics engineers, and cancer research scientists, on one hand, and AIkido and University of Texas Southwestern Medical Center research scientists, on the other, clearly pointed to how compelling and appropriate is the vision of Anthony Hayes for having AIkido use of these breakthrough biotech technologies in disease detection and drug development. We are excited and honored to be part of Anthony’s plan and effort.”

Anthony Hayes, CEO of AIkido stated, “We have completed several significant capital raises and are now putting that capital to work with the aim of achieving asymmetric rewards for our shareholders. As part of our goal to increase our use of AI and ML in drug development, our new research agreement with Cogia augments our pancreatic cancer research project with the University of Texas Southwestern Medical Center.  Cogia has significant depth and skill, as demonstrated by their notable client base.  We believe that Cogia can help us use machine learning to develop panels of markers to rapidly identify patients who have initiated early events in pancreatic cancer. Moreover, it is the goal of the machine learning protocols to identify which individuals are at risk for slow or rapid progression of the disease and catalyze the development of better early detection methods. It is our objective that the machine learning approach will help identify drugs best suited for potentially lifesaving individual patient treatment.  We are proud to partner with Cogia on this project.”

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-executes-artificial-intelligence-and-machine-learning-research-agreement-with-cogia-biotech-ltd-301054142.html

SOURCE AIkido Pharma Inc.